Background: Various symptoms have been associated with COVID-19, but little is known about the impacts of COVID-19 on the sensory system, risk factors, and the duration of symptoms. This study assesses olfactory, gustatory, hearing, and vestibular systems after COVID-19. Methods: This cross-sectional, single-center study involved 50 patients one to six months after COVID-19 and reports their patient records and the extent, onset, and duration of olfactory, gustatory, hearing, and balance disorders using questionnaires during and after COVID-19. Sensory symptoms were objectively studied using the following clinical tests after COVID-19 Sniffin’ Sticks, taste tests, tone/speech audiometry, and video head impulse test. Results: Post-COVID-19-patients were suffering from olfactory and gustatory impairment for up to six months. According to the Dizziness Handicap Inventory, balance disorders were less noticed: Overall, about 40% of the patients during COVID-19 and nearly all patients recovered within six months. After COVID-19, clinical tests revealed that 75% were suffering from hyposomnia/anosmia, and 20% of all patients reported mild hypogeusia for up to six months. Vestibular disorders and hearing impairment rarely/did not occur. Females were significantly more affected by sensory impairments than males. Conclusions: COVID-19 particularly caused olfactory and gustatory impairment; balance disorders were present too; vestibular and auditory symptoms were negligible.
Salivary duct carcinomas (SDC) of the parotid gland are rarely occurring highly malignant tumors. A 65-year-old man presented with a preauricular mass. After surgical treatment and histologic examination, the findings were interpreted as a squamous cell carcinoma (SCC) metastasis of the parotid gland deriving from a cancer of unknown primary DD primary SCC of the parotid gland. Adjuvant platinum-based radiochemotherapy was administered in domo. However, re-staging revealed multiple size-progressive pulmonary round lesions. After resection and histological examination of a pulmonary mass and in synopsis with the primary tumor, the initial diagnosis of SCC was revised to SDC of the parotid gland. With positive HER-2 status, off-label trastuzumab/docetaxel was initiated in an individual healing attempt, during which the pulmonary metastases showed clear progression. Consequently, the patient received immunotherapy with nivolumab according to his negative PD-L1 status. After 57 cycles of nivolumab, the patient presents with partial remission and in good condition. We report, for the first time, a robust response of metastatic SDC to checkpoint inhibition with nivolumab without additional radiotherapy.
Introduction: Auricular keloids may be associated with social stigma and impair patients’ quality of life (QoL) significantly. Little is known about the effect of different therapeutic concepts on the patient’s QoL. This study aims to investigate the QoL in patients with auricular keloids undergoing a specific multimodal therapeutic regimen. Materials and Methods: Patients suffering from auricular keloids were treated by a multimodal treatment comprising surgical excision, intralesional triamcinolone acetonide, and subsequent application of customized magnetic pressure splints. A prospective assessment of QoL was conducted using the validated Keloid Intervention Benefit Inventory-21 questionnaire at three time points. Results: In total, 22 auricular keloids were included in our study. All patients completed a comprehensive 1-year follow-up assessment, with an average follow-up duration of 29 months post-surgery. Quantitative analysis of QoL metrics demonstrated significant improvement of QoL at the three times of measurement ( P < .0001). Significant results were also found for the subcategories general health, physical health, social interaction, and self-esteem. Conclusion: This study underscores the necessity of assessment of QoL in keloid treatment. Our findings highlight the advantages of multimodal treatment in enhancing patients’ QoL throughout the treatment period and managing auricular keloids with low recurrence. Trial Registration: The study was registered at the German Clinical Trials Register (Register ID: DRKS00016348, https://drks.de/search/en/trial/DRKS00016348 ).
Introduction: Measurement of health-related quality of life (QoL) is a firmly established method for evaluating therapeutic procedures. Studies have demonstrated positive effects of passive music interventions. To date, however, no standardized approach to music therapy interventions after head and neck surgery has been developed. Furthermore, the effects of such interventions in the immediate postoperative phase following surgery in head and neck region have yet to be adequately investigated. Methods: Patients undergoing tonsillectomy were consecutively included in a prospective randomized study. The intervention group received passive music therapy (60 minutes/day). QoL was recorded using the Glasgow Benefit Inventory (GBI) and Brief Pain Inventory (BPI) at 3 fixed time points after operation. In addition, the participants filled out a pain diary throughout the observation period using a Visual Analog Scale. Results: Study sample comprised 31 patients. Fifteen patients (6 women and 9 men) were included in the intervention group and 16 (6 women and 10 men) in the control group. Participants’ average ages were 28 years (intervention group) and 39 years (control group). Significant differences in QoL emerged 5 and 14 days after surgery ( P = .049 and <.01). In addition, the BPI results differed significantly at time point 3 ( P < .01). Significant differences were observed in the pain diary from day 8 after surgery. Discussion/Conclusion: Complementary music interventions may improve QoL as well as patients’ pain perception. Owing to its ubiquitous availability and cost-effectiveness, passive music interventions with their measurable positive benefits may be easily implemented into clinical routine.